P2P review · Anti-HER2
Trastuzumab (Herceptin) P2P review prep
Anti-HER2. Indications: HER2+ breast cancer, gastric
Drug class
Anti-HER2
Payer criteria typically applied
- HER2 IHC 3+ or FISH amplified
- Stage + treatment intent
Common medical director objections
- HER2 testing required
- Biosimilar preferred
Pitfalls to avoid
- Biosimilar substitution
Frequently asked questions
What does the payer typically require for Trastuzumab (Herceptin)?
HER2 IHC 3+ or FISH amplified; Stage + treatment intent.
What objections does the medical director typically raise?
HER2 testing required; Biosimilar preferred.
What pitfalls should I avoid during the P2P call?
Biosimilar substitution.
Sources
Prep Trastuzumab (Herceptin) P2Ps faster — try ApprovalHelp free
ApprovalHelp auto-prepares P2P talking points from the patient's chart, surfaces payer-specific objections, and generates the post-call appeal draft. no setup fee.
Get started →Contact: hello@approvalhelp.com